News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,310 Results
Type
Article (1107)
Company Profile (4)
Press Release (3199)
Multimedia
Podcasts (11)
Webinars (1)
Section
Business (1308)
Career Advice (59)
Deals (175)
Drug Delivery (6)
Drug Development (1185)
Employer Resources (11)
FDA (217)
Job Trends (464)
News (2634)
Policy (397)
Tag
Academia (28)
Accelerated approval (3)
Allergies (5)
Alliances (280)
Alzheimer's disease (7)
Antibody-drug conjugate (ADC) (2)
Approvals (218)
Artificial intelligence (4)
Autoimmune disease (1)
Automation (1)
Bankruptcy (3)
Best Places to Work (392)
Biosimilars (15)
Biotechnology (3)
Brain cancer (1)
Breast cancer (2)
Cancer (47)
Cardiovascular disease (6)
Career advice (46)
Career pathing (2)
CAR-T (2)
CDC (1)
Cell therapy (13)
Clinical research (876)
Collaboration (17)
Compensation (1)
Complete response letters (6)
COVID-19 (187)
CRISPR (5)
C-suite (4)
Data (50)
Denatured (3)
Diabetes (3)
Diagnostics (32)
Digital health (1)
Diversity (3)
Diversity, equity & inclusion (3)
Drug discovery (2)
Drug pricing (6)
Duchenne muscular dystrophy (3)
Earnings (595)
Editorial (2)
Employer branding (7)
Employer resources (10)
Events (592)
Executive appointments (4)
FDA (254)
Funding (11)
Gene editing (11)
Gene therapy (22)
GLP-1 (37)
Government (120)
Grass and pollen (1)
Guidances (8)
Healthcare (123)
IgA nephropathy (1)
Immunology and inflammation (24)
Indications (1)
Infectious disease (190)
Influenza (1)
Intellectual property (1)
Interviews (11)
IPO (106)
IRA (1)
Job creations (89)
Job search strategy (45)
Labor market (4)
Layoffs (20)
Legal (56)
Liver cancer (2)
Lung cancer (9)
Lymphoma (4)
Management (2)
Manufacturing (16)
MASH (1)
Medical device (20)
Medtech (20)
Mergers & acquisitions (82)
Metabolic disorders (28)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (13)
NextGen: Class of 2025 (58)
Non-profit (15)
Now hiring (20)
Obesity (23)
Opinion (6)
Pain (2)
Patents (7)
Patient recruitment (1)
Peanut (1)
People (380)
Pharmaceutical (1)
Phase I (271)
Phase II (348)
Phase III (491)
Pipeline (40)
Policy (5)
Postmarket research (19)
Preclinical (72)
Rare diseases (13)
Real estate (32)
Recruiting (3)
Regulatory (314)
Reports (2)
Research institute (17)
Resumes & cover letters (6)
RNA editing (1)
RSV (2)
Series A (5)
Series B (3)
Sickle cell disease (1)
Special edition (2)
Spinal muscular atrophy (2)
Startups (14)
Tariffs (11)
The Weekly (8)
Vaccines (25)
Venture capital (3)
Weight loss (18)
Women's health (2)
Date
Last 7 days (13)
Last 30 days (26)
Last 365 days (393)
2025 (250)
2024 (387)
2023 (354)
2022 (557)
2021 (555)
2020 (535)
2019 (333)
2018 (237)
2017 (237)
2016 (167)
2015 (154)
2014 (105)
2013 (108)
2012 (81)
2011 (59)
2010 (45)
Location
Africa (23)
Asia (164)
Australia (58)
California (55)
Canada (7)
China (2)
Colorado (1)
Connecticut (5)
Delaware (2)
Europe (825)
Florida (1)
Georgia (1)
Idaho (1)
Illinois (9)
India (1)
Indiana (4)
Iowa (1)
Japan (1)
Maryland (1)
Massachusetts (51)
Michigan (1)
Minnesota (1)
Nebraska (1)
New Hampshire (3)
New Jersey (10)
New York (129)
North Carolina (9)
Northern California (36)
Ohio (3)
Oregon (1)
Pennsylvania (8)
Rhode Island (1)
South America (23)
South Carolina (1)
Southern California (8)
Texas (1)
United States (264)
Virginia (3)
Washington D.C. (2)
Washington State (5)
Wisconsin (1)
4,310 Results for "Regeneron".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2
Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO Leonard Schleifer told investors.
August 1, 2025
·
2 min read
·
Tristan Manalac
Accelerated approval
Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity
While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing convenience and efficacy.
July 3, 2025
·
2 min read
·
Tristan Manalac
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
June 2, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.
June 16, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
Regeneron promised to comply with 23andMe’s consumer privacy policies and related data security laws.
May 19, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Action Alert: Regeneron, Sanofi and Abeona
Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for Regeneron, one with partner Sanofi.
April 14, 2025
·
3 min read
·
Tristan Manalac
Manufacturing
Roche, Regeneron Pledge Multibillion Boosts to US Manufacturing as Trump’s Tariffs Loom
Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to “nearly double” its U.S. large-scale manufacturing capacity.
April 22, 2025
·
2 min read
·
Tristan Manalac
Legal
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea.
March 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Regeneron Reports Second Quarter 2025 Financial and Operating Results
August 1, 2025
·
30 min read
FDA
FDA Action Alert: Roche, GSK, Regeneron, More
The FDA has several big-ticket decisions lined up to close out July, including applications in lymphoma, rare diseases and a hormone deficiency, while GSK dares to DREAMM again in multiple myeloma.
July 14, 2025
·
7 min read
·
Tristan Manalac
1 of 431
Next
